Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of Evaluating the Combination of MK-3475 and Stereotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC

NCT02407171 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT02407171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02407171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of Evaluating the Combination of MK-3475 and Stereotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
Lead sponsor
Yale University
Phase
Phase 1/2
Overall status
Completed
Start date
April 1, 2015
Completion date
February 19, 2019
Enrollment
61 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, melanoma